Cargando…
Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
Background: About a third of patients with inflammatory bowel disease do not respond to anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the current data on the two main strategies when facing primary non-response to an anti-TNF agent in inflammatory bowel disease...
Autores principales: | Gisbert, Javier P., Chaparro, María |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625924/ https://www.ncbi.nlm.nih.gov/pubmed/34830595 http://dx.doi.org/10.3390/jcm10225318 |
Ejemplares similares
-
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
por: Gisbert, Javier P., et al.
Publicado: (2023) -
TNF and anti-TNF agents in Behçet's disease
por: Calamia, KT
Publicado: (2003) -
Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis
por: Guberna, Laura, et al.
Publicado: (2021) -
Investigation of the effects of anti-TNF agents on hemoglobin levels in patients with inflammatory bowel disease
por: Okuyucu, Muhammed, et al.
Publicado: (2022) -
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Cassandra, Rayer, et al.
Publicado: (2022)